Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.39 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8739184 | 0.91 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL1654021 | 0.91 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL8739307 | 0.87 | KDM4E (0.53) | PTGDR2TBXA2RPTGDRCTNNB1TCF7L2 | |
| SCHEMBL8739349 | 0.86 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL8738085 | 0.84 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL12952844 | 0.82 | PTGDR2 (0.60) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL1010102 | 0.81 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL1008774 | 0.81 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL15746411 | 0.81 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL8738858 | 0.81 | PTGDR2 (0.49) | PTGDR2TBXA2RPTGDRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | HRH2, HRH1, HRH4 | PTGDR2 11/4885TBXA2R 20/4885PTGDR 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.